Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.
The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.
The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.
This story was originally published by marketwatch.com. Use the link below to read the full article at the source.
Share
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
